Exploring novel prognostic biomarkers and biologic processes involved in NASH, cirrhosis and HCC based on survival analysis using systems biology approach
S Behrouzifar - arXiv preprint arXiv:2306.16184, 2023 - arxiv.org
There is an unmet need to develop medications or drug combinations which can stop
advancement of NASH to liver cirrhosis and HCC. Therefore, identifying key biomarkers …
advancement of NASH to liver cirrhosis and HCC. Therefore, identifying key biomarkers …
Hsa_circ_0002111/miR-557/DUSP14 axis mediates euthyrox-resistance in papillary thyroid cancer
J Zhou, J Liu, W Ma, P Zhao - STEMedicine, 2022 - stemedicine.org
As one of the most commonly used chemotherapeutic drug for papillary thyroid cancer
(PTC), euthyrox affects the therapeutic outcome due to the resistance of euthyrox …
(PTC), euthyrox affects the therapeutic outcome due to the resistance of euthyrox …